Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 12/20 | 0.60 |
| ▸ | PRKCQ | Q04759 | 12/20 | 0.60 |
| ▸ | PRKCH | P24723 | 11/20 | 0.60 |
| ▸ | PRKCE | Q02156 | 11/20 | 0.60 |
| ▸ | PRKCD | Q05655 | 11/20 | 0.60 |
| ▸ | PRKCB | P05771 | 10/20 | 0.60 |
| ▸ | JAK3 | P52333 | 7/20 | 0.50 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.49 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 4/20 | 0.45 |
| ▸ | JAK2 | O60674 | 3/20 | 0.45 |
| ▸ | TYK2 | P29597 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4357973 | 0.88 | PRKCA (0.60) | PRKCAPRKCQPRKCHPRKCEPRKCD | |
| SCHEMBL3553151 | 0.86 | JAK3 (0.59) | PRKCAPRKCQPRKCHPRKCEPRKCD | |
| SCHEMBL989940 | 0.85 | PRKCH (0.61) | PRKCAPRKCQPRKCHPRKCEPRKCD | |
| SCHEMBL3546174 | 0.85 | PRKCA (0.73) | PRKCAPRKCQPRKCHPRKCEPRKCD | |
| SCHEMBL4360100 | 0.84 | PRKCA (0.57) | PRKCAPRKCQPRKCHPRKCEPRKCD | |
| SCHEMBL4359156 | 0.83 | PRKCA (0.55) | PRKCAPRKCQPRKCHPRKCEPRKCD | |
| SCHEMBL990596 | 0.82 | PRKCA (0.60) | PRKCAPRKCQPRKCHPRKCEPRKCD | |
| SCHEMBL990732 | 0.82 | PRKCA (0.57) | PRKCAPRKCQPRKCHPRKCEPRKCD | |
| SCHEMBL991235 | 0.81 | PRKCH (0.61) | PRKCAPRKCQPRKCHPRKCEPRKCD | |
| SCHEMBL12949132 | 0.79 | PRKCA (0.56) | PRKCAPRKCQPRKCHPRKCEPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1747216-B1 | SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS | NOVARTIS AG (CH) | 2014-01-08 | — | — | EP | claimed |
| US-7851475-B2 | Substituted pyrrole-2, 5-diones as protein kinase C inhibitors | NOVARTIS AG (CH) | 2010-12-14 | — | — | US | claimed |
| US-20090221605-A1 | SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS | NOVARTIS AG (CH) | 2009-09-03 | — | — | US | claimed |
| EP-1747216-A1 | SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS | Novartis Pharma AG. (CH) | 2007-01-31 | — | — | EP | claimed |
| WO-2005113545-A1 | SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS | NOVARTIS AG (CH) | 2005-12-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221605-A1 | SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS | PRKCA, PRKCB, PRKCE | PRKCA 1/4885PRKCQ 12/4885PRKCH 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.